Geneva, 20 February 2020 – The Medicines Patent Pool (MPP) today announced that it signed a sublicence agreement and partnered with Mylan, a global pharmaceutical company, to develop, manufacture and supply the first generic version of glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for hepatitis C virus (HCV)infections. G/P is the only all oral, once-daily pan-genotypic combination regimen recommended by WHO that is currently not available as a generic medicine. The two organisations have entered an agreement to undertake G/P manufacturing henceforth and boost the supply to make it accessible to Hepatitis C patients. “We are pleased that, thanks to this sublicence agreement, Mylan will soon be able to increase access to the first generic version of G/P in developing countries, and supply affordable, quality-assured versions of this key treatment for treating HCV,” said Charles Gore, MPP Executive Director. In November 2018, MPP signed a royalty-free licence a...

Geneva, 5 February 2020 - As the World Health Organization (WHO) and the global health community work to identify the best course of treatment in the fight against the novel coronavirus (2019-nCov), the Medicines Patent Pool (MPP) is ready to support access to treatment through its voluntary licensing mechanism in low- and middle- income countries. MPP works with a wide range of treatments and holds licences for HIV antiretrovirals (ARVs) that may be effective in the treatment of 2019-nCov. MPP is currently monitoring developments closely to ensure equitable access to effective treatments. Increasing the scope of countries that a licence covers, as well as the use of ARVs for coronavirus treatment, is an opportunity for MPP to lend its model and expertise in assisting in the fight against the novel coronavirus outbreak.